Compounding Pharmacies and Peptides

Somewhere around 2022, a recurring pattern started showing up in Australian fitness and wellness communities: people comparing notes on peptide injections sourced through what were described as "compounding pharmacies" , sometimes with a script, sometimes without, often with little clarity on what exactly was being compounded or whether it was legal. I've spent enough time with the pharmacokinetics literature to know that the chemistry here is genuinely interesting. But the regulatory picture matters just as much as the molecules, and I reckon it's consistently under-explained.

So let's be precise about where things actually stand.

What compounding pharmacies do , and what they don't

Compounding pharmacies prepare individualised medicines for specific patients when a commercially available product either doesn't exist or doesn't suit the patient's needs. A legitimate compounding pharmacist might, for example, prepare a lower-strength formulation for a paediatric patient, or reformulate a product to exclude an allergen. This is a lawful, regulated, and genuinely useful part of the Australian medicines landscape.

What compounding pharmacies are not authorised to do is manufacture and supply unapproved medicines at scale , including peptides that have no current approval on the Australian Register of Therapeutic Goods (the ARTG). The distinction between patient-specific compounding and de facto manufacturing is exactly where enforcement action has been concentrating.

The Therapeutic Goods Administration has been explicit on this. Its 2023 guidance and subsequent compliance activity made clear that supplying compounded peptides; particularly those promoted for body composition, recovery, or anti-ageing, without appropriate regulatory authorisation is illegal under the Therapeutic Goods Act 1989. That's not a soft warning; penalties can include substantial fines and criminal prosecution for suppliers.

Which peptides are actually in scope

Not all peptides are regulated the same way. Some are registered medicines on the ARTG and are available under Schedule 4 (prescription only) pathways. A handful sit under Schedule 8 controls. But a significant number of peptides circulating in the performance and wellness space, including certain growth hormone-releasing peptides and their analogues; are either unregistered or explicitly prohibited from supply outside of approved research or clinical frameworks.

To understand why this matters pharmacologically, it helps to go back to basics. Peptides are short chains of amino acids joined by peptide bonds. Their biological activity depends heavily on sequence, conformation, and route of administration. Many are administered via subcutaneous injection precisely because oral delivery would expose them to gastrointestinal proteases before they reach the bloodstream, a bioavailability problem you can't ignore. This also means the formulation matters enormously: a compounded injectable peptide that has been poorly prepared, stored incorrectly, or contaminated carries real risk of sterility failure, endotoxin contamination, or inaccurate dosing.

The TGA's concerns aren't abstract. Independent testing of some compounded injectables in Australia has found products that don't match their labelled concentration, or that fail sterility requirements. These are the hard yards of pharmaceutical manufacturing quality, and they exist precisely because compounding at scale, without the oversight applied to registered medicines, creates meaningful room for error.

The GLP-1 situation is a useful case study

The GLP-1 receptor agonist class offers probably the clearest recent example of how compounding and peptide regulation intersect in a way that generates genuine public confusion. When demand for registered GLP-1 medicines outpaced supply in 2023–2024, compounding pharmacies began producing semaglutide and tirzepatide preparations. The TGA's position shifted across that period; at various points permitting limited supply during shortage, then tightening conditions, then issuing further guidance as the shortage status changed.

The lesson from that episode, I'd argue, isn't that compounding is inherently unsafe. It's that the legal ground can shift faster than consumer awareness. Someone who started using a compounded GLP-1 preparation under one set of conditions may have found themselves in a legally and clinically different situation six months later without any obvious signal that things had changed. That structural lag between regulatory status and public understanding is, honestly, one of the things that frustrates me most about how this space is communicated.

Good Manufacturing Practice and why it's not optional

Registered therapeutic goods in Australia must be manufactured in compliance with Good Manufacturing Practice (GMP), a framework covering everything from raw material testing to environmental monitoring of sterile manufacturing suites. Compounding pharmacies operate under a different, less stringent set of standards, which is appropriate for genuine patient-specific compounding but creates significant quality gaps when the same infrastructure is used to produce injectable peptides at quasi-commercial volumes.

The TGA's guidance distinguishes between "traditional compounding" (a specific patient, a valid prescription, a product not commercially available) and what it describes as "manufacturing", which is subject to the full registration and GMP requirement. The volume thresholds, the absence of individual patient prescriptions, and the overt promotion of peptides for performance or cosmetic purposes are all factors that push activity from the former category into the latter. Supplying that way without TGA approval is illegal, full stop.

Accessing peptides lawfully in Australia

For peptides that are unapproved but have a legitimate clinical application being investigated, there are two pathways: the Special Access Scheme (SAS) and the Authorised Prescriber scheme. Both require a medical practitioner to be involved, both impose conditions and notification requirements, and neither is a mechanism for general wellness or performance use. They exist for patients with genuine clinical need where no approved alternative exists.

The pharmacokinetics of peptide medicines are also genuinely complex; half-lives, receptor binding kinetics, degradation pathways, and these properties vary significantly between structurally similar compounds. This is another reason why "I found a pharmacy that'll compound it" is a much more fraught starting point than it sounds. Even where a practitioner is involved, the clinical pharmacology of many of these compounds in humans is still being characterised.

I was reading through a TGA compliance update last month while waiting for a long run to feel less terrible, somewhere around the 14-kilometre mark; and what struck me was how clearly the language has hardened. Words like "illegal supply", "enforcement action", and references to the Therapeutic Goods Act 1989 penalties appear with notable frequency in the recent peptide-related guidance. This is not the TGA hedging.

What this means for people reading about peptides online

The peptide content that dominates wellness social media in Australia sits in a strange space: detailed, confident, sometimes citing real research, but almost never engaging honestly with the regulatory framework. That's a gap worth naming.

Understanding what a peptide does at the receptor level, or how its structure influences its half-life, is legitimately interesting science. That's what we write about here. But the classification of a compound under the Poisons Standard, its ARTG status, who can lawfully supply it, under what conditions, and what enforcement looks like, those aren't footnotes. They're the frame the rest of the information sits inside.

If a substance is being described to you as "available through a compounding pharmacy" without a specific, named registered product context and a valid prescription pathway, it's worth asking what exactly makes that supply lawful. The answer isn't always reassuring.

Sources

• Compounding medicines in Australia, Therapeutic Goods Administration (TGA)
• TGA takes action on illegal supply of peptides; Therapeutic Goods Administration (TGA)
• Therapeutic Goods Act 1989, Federal Register of Legislation
• Peptide therapeutics: current status and future directions, NCBI / National Library of Medicine

, Priya Nandakumar, Pharmacology writer; peptides & PK